NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

NRIX | NASDAQ

$26.02 -$0.08 | -0.31%

TREND SIGNAL: Signal available — unlock to view

Signal available — unlock to view

|2026-10-21

Add to favoritesFavorite

Company Overview:

Market Cap: $2.90B

Trailing PE: —

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $10.28 - $28.23

6.2 Year NRIX Performance Metrics:

Total Return (with DRIP): 36.9% (5.19% CAGR)

Total Return (no DRIP): 36.9% (5.19% CAGR)

Share Price: 36.9% (5.19% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $13,688

Total Return $ (with DRIP): $3,688

NRIX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

NRIX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan

PRO

$171/yr ($14.25/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $57/yr (25%)

Most Popular

PREMIUM

$288/yr ($24/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $96/yr (25%)

ULTRA

$576/yr ($48/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $192/yr (25%)

NRIX Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

NRIX - Revenue

NRIX Revenue CAGR:1Y: -79.47%2Y: -13.52%5Y: 4.98%10Y: 0.00%

NRIX - Earnings Per Share (EPS)

NRIX EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Net Income

🔓 See the full chart7-day free trial

NRIX Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - EBITDA

🔓 See the full chart7-day free trial

NRIX EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Free Cash Flow

🔓 See the full chart7-day free trial

NRIX Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Free Cash Flow / Share

🔓 See the full chart7-day free trial

NRIX Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Operating Income

🔓 See the full chart7-day free trial

NRIX Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Gross Profit

🔓 See the full chart7-day free trial

NRIX Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Shares Outstanding

🔓 See the full chart7-day free trial

NRIX Shares Outstanding CAGR:1Y: 32.43%2Y: 33.45%5Y: 20.46%10Y: 0.00%

NRIX - Share Buybacks

🔓 See the full chart7-day free trial

NRIX Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Stock-Based Comp

🔓 See the full chart7-day free trial

NRIX Stock-Based Comp CAGR:1Y: 9.66%2Y: 13.47%5Y: 23.62%10Y: 0.00%

NRIX - Expenses

🔓 See the full chart7-day free trial

NRIX Expenses CAGR:1Y: -27.63%2Y: -0.03%5Y: -1.53%10Y: 0.00%

NRIX - Revenue vs Net Income

🔓 See the full chart7-day free trial

NRIX - EPS vs FCF / Share

🔓 See the full chart7-day free trial

NRIX - EPS vs PE Ratio

🔓 See the full chart7-day free trial

NRIX - FCF vs FCF / Share

🔓 See the full chart7-day free trial

NRIX - FCF vs Stock Based Comp

🔓 See the full chart7-day free trial

NRIX - Cash & Debt

🔓 See the full chart7-day free trial

NRIX - Revenue by Segment

🔓 See the full chart7-day free trial

NRIX Revenue CAGR:1Y: -79.47%2Y: -13.52%5Y: 4.98%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

NRIX - REVENUE: Actual + Estimates

🔓 See the full chart7-day free trial

NRIX Actual Revenue CAGR:1Y: -79.47%2Y: -13.52%5Y: 4.98%10Y: 0.00%

NRIX - EPS: Actual + Estimates

🔓 See the full chart7-day free trial

NRIX Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - NET INCOME: Actual + Estimates

🔓 See the full chart7-day free trial

NRIX Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - EBITDA: Actual + Estimates

🔓 See the full chart7-day free trial

NRIX Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

NRIX - Net Profit Margin

🔓 See the full chart7-day free trial

NRIX Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Gross Profit Margin

🔓 See the full chart7-day free trial

NRIX Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Price to Earnings

🔓 See the full chart7-day free trial

NRIX Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Price To Sales Ratio

🔓 See the full chart7-day free trial

NRIX Price To Sales Ratio CAGR:1Y: 955.46%2Y: 62.15%5Y: 3.89%10Y: 0.00%

NRIX - Return on Capital Employed

🔓 See the full chart7-day free trial

NRIX Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

NRIX - Return on Invested Capital

🔓 See the full chart7-day free trial

NRIX Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for NRIX

Based on past 6.2-year performance, here are NRIX growth metrics:

Share price CAGR of +5.19%
Dividend CAGR of +0%

Using NRIX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	NRIX (DRIP)	NRIX - No DRIP
Current Price	$26.02	$26.02
Start Shares	384.32	384.32
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	384.32	384.32
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$26.02	$26.02
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - NRIX

NOTE: Above numbers are our estimate based on NRIX's Dividend and Price CAGR over past 6.2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan

PRO

$171/yr ($14.25/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $57/yr (25%)

Most Popular

PREMIUM

$288/yr ($24/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $96/yr (25%)

ULTRA

$576/yr ($48/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $192/yr (25%)

Company Info

Nurix Therapeutics, Inc. (NRIX) had its IPO on 2020-07-24, and is traded on NASDAQ stock exchange.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

NRIX website: https://www.nurixtx.com

Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan

PRO

$171/yr ($14.25/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $57/yr (25%)

Most Popular

PREMIUM

$288/yr ($24/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $96/yr (25%)

ULTRA

$576/yr ($48/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $192/yr (25%)

Loading signals…

DCF Model — NRIX

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $26.02

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own NRIX? See every dividend it's paid you

Add your NRIX shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every NRIX dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my NRIX payments →

Free plan · up to 5 holdings